Search clinical trials for: 0.8mU Insulin

Total 2808 results

Novo Nordisk A/S

Completed

Comparison of Hypoglycaemic Response Between NN1250 and Insulin Glargine in Type 1 Diabetics

Diabetes | Diabetes Mellitus, Type 1

Austria
Sanofi

Completed

Self Titration With Apidra to Reach Target Study (START)

Diabetes Mellitus, Type 2

Canada
Geropharm

Completed

Efficacy and Safety of GP40071 Compared to NovoRapid® Penfill® in Type 1 Diabetes Mellitus Patients

Diabetes | Diabetes Mellitus, Type 1

Russian Federation
Medical University of Warsaw

Unknown

Insulin Requirement for Pure-protein Meal in Children With Type 1 Diabetes on Insulin Pumps.

Diabetes type1

Poland
Rush University Medical Center
Novo Nordisk A/S

Completed

Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol.

Type 2 Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine

Diabetes Mellitus, Type 2

United States, Italy, Canada, Germany, Czechia
Novo Nordisk A/S

Completed

Within-subject Variability of Insulin Detemir in Children and Adolescents With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Germany, United Kingdom, Austria, Belgium, France, Ireland
Novo Nordisk A/S

Completed

Efficacy and Safety of a Fixed or a Flexible Supplementary Insulin Therapy in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

An Observational Study of Insulin Aspart and, if Necessary, Insulin Levemir (FlexPen®) in the Evening or at Bedtime

Diabetes Mellitus, Type 2 | Diabetes

Germany
Sanofi

Completed

Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)

Diabetes Mellitus

United States
Sanofi

Completed

Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs (CHANGING)

Diabetes Mellitus, Type 2

Algeria, Brazil, Israel, Lebanon, Mexico, Morocco, Peru, Saudi Arabia, United Arab Emirates, Venezuela
Novo Nordisk A/S

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Explorative Formulation of Insulin Degludec

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

Austria
Novo Nordisk A/S

Completed

Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Characteristics of Explorative Formulations of Insulin Degludec and IDegAsp 50 in Healthy Japanese Subjects

Healthy | Diabetes

Germany
Steno Diabetes Center Copenhagen
Zealand University Hospital; Novo Nordisk A/S; Rigshospitalet, Denmark; Hvidovre... and other collaborators

Completed

The Copenhagen Insulin and Metformin Therapy Trial (CIMT)

Arteriosclerosis | Atherosclerosis | Type 2 Diabetes

Denmark
Mount Sinai Hospital, Canada
Canadian Institutes of Health Research (CIHR); University of Toronto

Completed

Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL) (PREVAIL)

Type 2 Diabetes

Canada
AstraZeneca
Eli Lilly and Company

Completed

Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin

Diabetes Mellitus, Type 2

Taiwan, United Kingdom, Portugal, Spain, Netherlands, Croatia, Slovenia, Greece, Italy, Germany, Romania, Russian Federation
Halozyme Therapeutics

Completed

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type II

United States
Novo Nordisk A/S

Completed

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

Diabetes Mellitus, Type 2

India, United States, Thailand, Japan, Germany, Turkey, Hungary, Malaysia, Poland, South Africa, Czechia, Italy, France, Slovenia
Rush University Medical Center
Novo Nordisk A/S

Completed

Subcutaneous Aspart Insulin to Treat Diabetic Ketoacidosis (DKA) and Beta-Hydroxybutyrate Testing in DKA (DKA)

Diabetic Ketoacidosis

United States
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Bioequivalence Study of INS062 and Pharmacokinetics and Pharmacokinetics Study of Single Injection of HR20014 in Healthy Subjects

Diabetes

China
Eli Lilly and Company

Completed

A Study for Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Brazil, Canada, Mexico, India, Australia, China, Korea, Republic of
Sunshine Lake Pharma Co., Ltd.

Not yet recruiting

A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China

Diabetes
Novo Nordisk A/S

Completed

Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes (EXPECT)

Diabetes | Diabetes Mellitus, Type 1

Israel, Italy, Russian Federation, United Kingdom, Denmark, Austria, Serbia, Canada, Croatia, Australia, Greece, Ireland, Brazil, Spain, Argentina
Novo Nordisk A/S

Completed

Within-subject Variability of Insulin Detemir in Healthy Volunteers

Healthy | Diabetes

Germany
University of Sao Paulo General Hospital

Completed

Glargine Versus NPH in Patients With Chronic Kidney Disease

Type 2 Diabetes Mellitus | Chronic Kidney Disease

Brazil
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus

Healthy | Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Efficacy and Safety of Insulin Aspart in MDI or CSII in Children Below 7 Years of Age With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Poland
Novo Nordisk A/S

Completed

A Trial Comparing the Effect of Exercise on Blood Glucose in Subjects With Type 1 Diabetes, Who Are Treated With Either Insulin Degludec or Insulin Glargine

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Biodel

Completed

Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes

Diabetes Mellitus Type 1

United States
University Hospital Tuebingen
Medical University of Vienna; University of Bern; CenTrial GmbH

Terminated

Weight Gain, Eating Patterns, and Development of Body Composition During Initiation of Basal Insulin Therapy in Patients With Type 2 Diabetes: A Comparison of Insulin Detemir and Insulin Glargine

Obesity | Diabetes

Austria, Germany, Switzerland
University of Pittsburgh
Sanofi

Completed

Effect of Glargine Insulin on Glucose Control in Hospitalized Patients Who Receive Tube Feedings

Hyperglycemia | Type 2 Diabetes

United States
Emory University

Completed

Sitagliptin in Non-Diabetic Patients Undergoing General Surgery

Hyperglycemia

United States
Novo Nordisk A/S

Completed

Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

China
US Department of Veterans Affairs

Completed

Insulin Secretion in Diabetes Before and After Glycemic Control

Hyperglycemia | Diabetes

United States
Amphastar Pharmaceuticals, Inc.

Completed

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers

Pharmacokinetics | Pharmacodynamics

United States
Fundación Pública Andaluza para la Investigación...

Completed

Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study) (INEOX)

Type 1 Diabetes Mellitus

Spain
Wockhardt

Completed

Comparative Wockhardt's Glucose Clamp Study-Human Isophane Susp 30IU/ml/70IU/ml With Novolin70/30, in Healthy Subjects

Diabetes Mellitus

United States
Novo Nordisk A/S

Recruiting

A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes

Diabetes, Type 2

United States, India, Spain, Poland, South Africa, Bulgaria, Germany, Japan, Puerto Rico
Ain Shams University

Not yet recruiting

Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia

Critical Illness | Insulin | Glycemic Control
Novo Nordisk A/S

Completed

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

Diabetes Mellitus, Type 2

Poland, United States, Croatia, Spain, Slovakia, Germany, Hungary
Novo Nordisk A/S

Completed

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, India, Italy, Mexico, Russian Federation, United Kingdom, Spain, Malaysia, Croatia, Greece, Korea, Republic of, Japan, South Africa, Algeria, Thailand, Argentina, Brazil, Canada, Romania
Novo Nordisk A/S

Completed

Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Evaluating the Effect of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

Korea, Republic of, Japan, Malaysia, Taiwan, Thailand, Hong Kong
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Israel, Puerto Rico, Slovakia, Canada, South Africa, United Kingdom, Czech Republic
Novo Nordisk A/S

Completed

The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin

Diabetes Mellitus, Type 2 | Diabetes

United States
Novo Nordisk A/S

Completed

Efficacy and Safety of Insulin Aspart vs. Human Insulin During Pregnancy by Women With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United Kingdom, Denmark, Canada, France, Netherlands, Austria, Israel, Finland, Russian Federation, Croatia, Bulgaria, Poland, Ireland, Spain, Norway, Greece, Argentina, Germany

3

Subscribe